A retinoblastoma that only involves a single eye.
Comprehensive, easy-to-understand information about this condition
How we create this content →The documentation surrounding unilateral retinoblastoma is limited primarily due to its rarity, which affects fewer than a few thousand individuals worldwide. This rarity results in fewer systematic clinical studies and a lack of comprehensive data on clinical features and genetic factors. As research continues to evolve, there is hope that more information will become available to better understand and manage this condition.
To navigate your care effectively, it's crucial to seek a pediatric oncologist with experience in treating retinoblastoma. Additionally, consider reaching out to genetic counselors to discuss potential genetic implications, even though a genetic basis has not been established. For further resources, the National Organization for Rare Disorders (NORD) offers valuable information at rarediseases.org. Participating in clinical trials may also provide access to cutting-edge treatments and contribute to the understanding of this condition.
There are several orphan drugs in development for unilateral retinoblastoma, including Episcleral Topotecan, genetically modified human adenovirus encoding human PH20, and melphalan, among others. Currently, there are 6 active clinical trials aimed at exploring new treatment options. You can find more information on these trials at ClinicalTrials.gov by searching for 'unilateral retinoblastoma'. This ongoing research provides hope for improved treatment strategies in the future.
Actionable guidance for navigating care for unilateral retinoblastoma
To navigate your care effectively, it's crucial to seek a pediatric oncologist with experience in treating retinoblastoma. Additionally, consider reaching out to genetic counselors to discuss potential genetic implications, even though a genetic basis has not been established. For further resources, the National Organization for Rare Disorders (NORD) offers valuable information at rarediseases.org. Participating in clinical trials may also provide access to cutting-edge treatments and contribute to the understanding of this condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation surrounding unilateral retinoblastoma is limited primarily due to its rarity, which affects fewer than a few thousand individuals worldwide. This rarity results in fewer systematic clinical studies and a lack of comprehensive data on clinical features and genetic factors. As research continues to evolve, there is hope that more information will become available to better understand and manage this condition.
To navigate your care effectively, it's crucial to seek a pediatric oncologist with experience in treating retinoblastoma. Additionally, consider reaching out to genetic counselors to discuss potential genetic implications, even though a genetic basis has not been established. For further resources, the National Organization for Rare Disorders (NORD) offers valuable information at rarediseases.org. Participating in clinical trials may also provide access to cutting-edge treatments and contribute to the understanding of this condition.
There are several orphan drugs in development for unilateral retinoblastoma, including Episcleral Topotecan, genetically modified human adenovirus encoding human PH20, and melphalan, among others. Currently, there are 6 active clinical trials aimed at exploring new treatment options. You can find more information on these trials at ClinicalTrials.gov by searching for 'unilateral retinoblastoma'. This ongoing research provides hope for improved treatment strategies in the future.
Actionable guidance for navigating care for unilateral retinoblastoma
To navigate your care effectively, it's crucial to seek a pediatric oncologist with experience in treating retinoblastoma. Additionally, consider reaching out to genetic counselors to discuss potential genetic implications, even though a genetic basis has not been established. For further resources, the National Organization for Rare Disorders (NORD) offers valuable information at rarediseases.org. Participating in clinical trials may also provide access to cutting-edge treatments and contribute to the understanding of this condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation surrounding unilateral retinoblastoma is limited primarily due to its rarity, which affects fewer than a few thousand individuals worldwide. This rarity results in fewer systematic clinical studies and a lack of comprehensive data on clinical features and genetic factors. As research continues to evolve, there is hope that more information will become available to better understand and manage this condition.
To navigate your care effectively, it's crucial to seek a pediatric oncologist with experience in treating retinoblastoma. Additionally, consider reaching out to genetic counselors to discuss potential genetic implications, even though a genetic basis has not been established. For further resources, the National Organization for Rare Disorders (NORD) offers valuable information at rarediseases.org. Participating in clinical trials may also provide access to cutting-edge treatments and contribute to the understanding of this condition.
There are several orphan drugs in development for unilateral retinoblastoma, including Episcleral Topotecan, genetically modified human adenovirus encoding human PH20, and melphalan, among others. Currently, there are 6 active clinical trials aimed at exploring new treatment options. You can find more information on these trials at ClinicalTrials.gov by searching for 'unilateral retinoblastoma'. This ongoing research provides hope for improved treatment strategies in the future.
Actionable guidance for navigating care for unilateral retinoblastoma
To navigate your care effectively, it's crucial to seek a pediatric oncologist with experience in treating retinoblastoma. Additionally, consider reaching out to genetic counselors to discuss potential genetic implications, even though a genetic basis has not been established. For further resources, the National Organization for Rare Disorders (NORD) offers valuable information at rarediseases.org. Participating in clinical trials may also provide access to cutting-edge treatments and contribute to the understanding of this condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.